Armour Thyroid and Natural Desiccated Thyroid: Complete Clinical Guide

What Is Armour Thyroid and How Is It Made?

Armour Thyroid is a desiccated thyroid extract manufactured from porcine (pig) thyroid glands that have been cleaned, dried, and powdered into standardized tablets. Each grain (60 mg) delivers approximately 38 mcg of levothyroxine (T4) and 9 mcg of liothyronine (T3), along with trace amounts of T1, T2, calcitonin, and thyroglobulin. The product has been used in clinical practice since the 1890s, predating the synthesis of levothyroxine by decades [1].

Standardization is performed by iodine content rather than by direct hormone assay, which is one reason endocrinologists sometimes raise variability concerns. A 2013 analysis published in Thyroid confirmed that hormone content in commercially available DTE products is generally consistent across lots, but small batch-to-batch variation does exist [2]. Patients with narrow therapeutic windows, such as those with atrial fibrillation or low bone mineral density, warrant closer monitoring for this reason.

NP Thyroid (Acella Pharmaceuticals) is the most commonly prescribed generic-equivalent DTE and uses the same porcine-derived raw material. Nature-Throid was withdrawn from the U.S. market in 2020 due to sub-potency concerns identified by the FDA [3]. Armour Thyroid and NP Thyroid remain available and FDA-regulated under cGMP standards.

Armour Thyroid vs. Levothyroxine (Synthroid): Which Works Better?

For most newly diagnosed hypothyroid patients, levothyroxine monotherapy normalizes TSH and resolves symptoms. A significant minority, estimated at 10 to 15 percent in population-based studies, report persistent fatigue, cognitive difficulty, and weight issues despite TSH in the reference range [4]. This is the population most likely to benefit from DTE or combination T4/T3 therapy.

The most cited head-to-head trial, the Hoang et al. (2013) study published in The Journal of Clinical Endocrinology and Metabolism (N=70), found that 49 percent of participants preferred DTE over levothyroxine, while 19 percent preferred levothyroxine. Patients on DTE lost an average of 4 pounds more during the trial period [5]. The authors noted the preference difference was statistically significant (P<0.001).

The American Thyroid Association's 2014 guidelines state: "Combination T4/T3 therapy remains an option for patients who have persistent symptoms of hypothyroidism despite serum TSH levels within the normal reference range on T4 monotherapy." [6] The ATA does not endorse DTE as a first-line choice, but it no longer classifies it as contraindicated.

Levothyroxine advantages over DTE include a longer half-life (roughly 7 days vs. 1 day for T3), once-daily dosing without significant T3 peaks, and decades of safety data in pregnancy. Tirosint, a liquid-gel soft-gel formulation of levothyroxine, eliminates most absorption issues tied to tablet fillers and is particularly useful for patients with celiac disease, bariatric surgery history, or concurrent proton pump inhibitor use [7].

How T3 Content Changes the Clinical Picture

Levothyroxine is a T4-only product. The body converts T4 to the active hormone T3 via deiodinase enzymes, primarily in the liver and kidney. Patients with the DIO2 Thr92Ala polymorphism may have reduced peripheral T4-to-T3 conversion, potentially explaining why some individuals feel better on a T3-containing therapy [8].

Liothyronine (Cytomel) is synthetic T3 at doses typically ranging from 5 to 25 mcg per day. It can be added to levothyroxine therapy as separate tablets rather than choosing DTE, giving the prescriber independent control over T4 and T3 doses. The fixed 4:1 ratio in DTE cannot be adjusted without changing the total dose, which limits fine-tuning. A 2019 meta-analysis in The Journal of Clinical Endocrinology and Metabolism reviewed 26 randomized trials and found combination T4/T3 therapy produced no statistically significant improvement in quality of life versus T4 alone across pooled populations, though subgroup benefits in patients with low free T3 remained plausible [9].

Free T3 levels matter here. When a patient's free T3 runs in the lower third of the reference range while TSH is normal, a prescriber may consider adding T3 or switching to DTE. Checking free T3 alongside TSH and free T4 at baseline is standard practice before initiating any combination protocol [6].

Dosing Armour Thyroid: Starting, Titrating, and Monitoring

Dosing starts conservatively and moves upward in increments. The typical adult starting dose is 30 mg (½ grain) per day for patients who are thyroid-hormone naive, or a calculated conversion dose for patients switching from levothyroxine. Labs are rechecked at 6 to 8 weeks after each adjustment [6].

The standard conversion ratio used in clinical practice is 60 mg (1 grain) of DTE to approximately 100 mcg of levothyroxine. This is an approximation. Because DTE contains a higher proportion of T3 relative to what the human thyroid produces (the human gland secretes roughly 20:1 T4:T3, not 4:1), patients switching to DTE often see TSH drop and free T3 rise. The target on DTE therapy is typically a TSH in the lower half of the reference range with free T4 and free T3 both within range [5].

Common titration schedule:

• Week 0: Initiate 30 mg daily (or converted dose from levothyroxine)
• Week 6, 8: Recheck TSH, free T4, free T3; increase by 15 to 30 mg if TSH remains above 2.5 mIU/L and symptoms persist
• Week 12, 16: Re-evaluate; most patients stabilize between 60 and 120 mg daily
• Every 6 months: Maintenance labs once dose is stable

Splitting the dose (morning and early afternoon) is sometimes recommended to blunt the T3 peak, though evidence for this approach in DTE specifically is limited [10].

NP Thyroid vs. Armour Thyroid: Practical Differences

NP Thyroid and Armour Thyroid are pharmacologically equivalent products with the same labeled hormone content per grain. Differences are largely formulaic. Armour Thyroid uses calcium stearate as a lubricant and is manufactured by AbbVie. NP Thyroid uses a simpler inactive-ingredient list, which some patients with dye sensitivities or corn allergies prefer. Neither is interchangeable at the pharmacy without prescriber authorization, because switching brands mid-therapy can cause measurable TSH shifts in sensitive patients [11].

During the 2020 NP Thyroid shortage and the 2019 Nature-Throid recall, many patients were forced to switch brands abruptly. Rechecking TSH and free thyroid hormones within 6 weeks of any brand change is the appropriate response, not waiting the standard 6-month interval.

Tirosint and Liquid Levothyroxine: When Standard Tablets Fail

Tirosint (levothyroxine sodium in a liquid-gel cap) provides T4 without the common excipients, acacia, lactose, and cornstarch, found in standard levothyroxine tablets. Absorption studies show Tirosint reaches peak serum T4 concentration in roughly 2 hours versus 3 to 4 hours for tablet formulations, and pharmacokinetic variability is lower [7]. Patients who remain under-replaced despite adequate tablet doses, particularly those on proton pump inhibitors or H2 blockers, are good candidates for Tirosint.

A liquid oral solution of levothyroxine (Tirosint-SOL) is also available for patients who cannot swallow capsules or who require precise micro-dose adjustments, including pediatric patients and elderly patients with dysphagia. The FDA approved Tirosint-SOL in 2018 [12].

Clinicians at HealthRX apply the following three-step framework when selecting thyroid hormone formulation for a new patient:

1. Step 1 (standard): Levothyroxine tablet (generic or Synthroid) titrated to TSH 0.5, 2.5 mIU/L. Recheck at 6 weeks.
2. Step 2 (absorption concern): Switch to Tirosint or Tirosint-SOL if TSH remains elevated despite dose increases, especially with confirmed PPI use or GI malabsorption history.
3. Step 3 (persistent symptoms with normal TSH): Add liothyronine 5 mcg or switch to DTE (Armour or NP Thyroid) if free T3 is in the lower third of reference range and TSH is normal after at least 6 months on optimized T4 monotherapy.

Who Should Not Take Armour Thyroid?

Certain clinical scenarios favor avoiding DTE. Patients with known cardiovascular disease, particularly those with a history of atrial fibrillation or unstable angina, may be more sensitive to the T3 peaks that occur 2 to 4 hours after DTE ingestion. A 2018 Cochrane review on thyroid hormone replacement for subclinical hypothyroidism found no cardiovascular benefit from treatment in patients older than 65 with TSH <10 mIU/L, reinforcing caution about adding T3 in older cardiac patients [13].

Pregnancy is another area where levothyroxine monotherapy is preferred. The T3 component of DTE crosses the placenta differently than T4, and the fixed ratio cannot be adjusted to the trimester-specific T4 requirements that obstetric guidelines specify. The American College of Obstetricians and Gynecologists recommends maintaining TSH <2.5 mIU/L in the first trimester using levothyroxine [14]. Patients already stable on DTE who become pregnant should discuss the switch with both their endocrinologist and obstetrician promptly.

Adrenal insufficiency, whether primary or secondary, must be ruled out before initiating any thyroid hormone therapy. Increasing thyroid hormone clearance in a patient with untreated cortisol deficiency can precipitate an adrenal crisis [15].

Drug Interactions and Absorption Timing

Armour Thyroid, like all thyroid hormone formulations, has significant absorption interactions. Calcium carbonate, iron supplements, magnesium-containing antacids, and cholestyramine all reduce DTE absorption when taken within 4 hours. The FDA labeling for Armour Thyroid recommends taking the medication on an empty stomach, 30 to 60 minutes before food, and separating it from interfering supplements by at least 4 hours [16].

Key interactions:

• Warfarin: Thyroid hormones increase warfarin sensitivity; INR should be rechecked 4 to 6 weeks after any dose adjustment [17].
• Antidiabetic agents: Improved metabolic rate may alter insulin requirements; blood glucose monitoring frequency should increase during titration [15].
• Selective serotonin reuptake inhibitors: Sertraline and related drugs may accelerate T4 clearance, occasionally requiring dose increases in stable patients [17].
• Estrogen-containing oral contraceptives: Estrogen raises thyroxine-binding globulin, increasing total T4 and T3 binding; free hormone levels may fall, requiring dose adjustment [18].

Reading Your Thyroid Labs on DTE

Standard TSH-only monitoring is insufficient on DTE therapy. The T3 content suppresses TSH more per unit of T4 effect than levothyroxine alone does, meaning TSH may read low-normal or mildly suppressed even when the patient is not clinically over-replaced [5]. Checking free T4 and free T3 alongside TSH is the standard approach.

Target ranges used by most endocrinologists and thyroid-specialty clinicians for patients on DTE:

• TSH: 0.5 to 2.5 mIU/L (some clinicians accept as low as 0.1 if free T3 and T4 are in range and no cardiac risk)
• Free T4: mid-range for the laboratory's reference interval
• Free T3: mid to upper third of the laboratory's reference interval, without exceeding the upper limit

A 2017 study in Thyroid (N=168) found that patients on DTE had significantly higher free T3 and lower free T4 compared to patients on levothyroxine at equivalent TSH levels, confirming that interpreting labs without free T3 on DTE is incomplete [19]. Bone density and heart rate should be assessed annually in patients maintained on doses that produce a consistently low or suppressed TSH [6].

Switching from Levothyroxine to Armour Thyroid: Step-by-Step

Switching requires calculating a conversion dose, confirming adrenal function is intact, and setting a firm follow-up lab date. The process does not need to be complicated.

Step 1: Calculate the DTE equivalent. Take the current levothyroxine dose in mcg, divide by 100, and multiply by 60 mg. A patient on 150 mcg levothyroxine would start at approximately 90 mg (1.5 grains) of DTE. Many clinicians start 10 to 20 percent below this calculated dose to avoid over-replacement during the transition [5].

Step 2: Discontinue levothyroxine and begin DTE the following morning. There is no washout period needed because DTE contains T4, maintaining continuity.

Step 3: Recheck TSH, free T4, and free T3 at 6 weeks. Do not wait the standard 6-month interval used for stable levothyroxine patients, because the T3 component reaches steady state within days and dose adjustments may be needed sooner [10].

Step 4: Adjust in 15 to 30 mg increments based on labs and symptoms until the patient is stable for two consecutive 6-week lab cycles.

Step 5: Transition to 6-month monitoring once stable. Resume annual monitoring after 12 months of confirmed stability [6].

Cytomel (Liothyronine) as an Alternative to Switching

Some prescribers and patients prefer adding liothyronine (Cytomel, 5 or 10 mcg) to an existing levothyroxine regimen rather than switching to DTE outright. This approach preserves independent dose control and is easier to reverse if T3 is not tolerated. The trade-off is that it requires taking two separate medications, which some patients find inconvenient.

A 2006 trial published in The Journal of Clinical Endocrinology and Metabolism (N=46) compared LT4 monotherapy to LT4 plus LT3 combination and found no difference in neurocognitive outcomes but did note patient-reported mood improvement with combination therapy in a subset who had undergone total thyroidectomy [20]. The evidence remains mixed, and patient preference and free T3 status at baseline remain the strongest guides to clinical decision-making [9].

Extended-release liothyronine formulations are in development and may reduce the peak-trough variability that makes standard Cytomel less ideal for patients with cardiac concerns. Clinical trial data on extended-release LT3 are not yet sufficient to change prescribing practice.

Cost, Insurance, and Access Considerations

Armour Thyroid is a brand-name product with no AB-rated generic equivalent approved by the FDA as of early 2025. Cash prices range from approximately $40 to $90 per month depending on dose and pharmacy. NP Thyroid is the closest generic-equivalent and is substantially cheaper, often $15 to $40 per month, though formulary coverage varies by insurer.

Levothyroxine (generic) is one of the least expensive prescription medications in the United States, typically $4 to $15 per month at retail pharmacies. Synthroid (branded levothyroxine) costs substantially more without insurance. Tirosint carries the highest cash price among T4 formulations, often $80 to $150 per month without a manufacturer coupon.

Many telehealth thyroid prescribing platforms can initiate and manage DTE therapy after a lab-informed virtual consultation, which increases access for patients in underserved areas. Prescriptions for Schedule IV substances (which thyroid hormones are not) are not required, so interstate telemedicine prescribing of Armour Thyroid is legally permissible in all U.S. states [21].